A Phase 1 Study of LY2875358 in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Emibetuzumab (Primary) ; Erlotinib; Trametinib
- Indications Bone metastases; Cancer; Colon cancer; Gastrointestinal cancer; Liver cancer; Liver metastases; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Renal cell carcinoma; Solid tumours; Uveal melanoma
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 14 Feb 2017 Status changed from active, no longer recruiting to completed.
- 25 Jan 2017 Planned End Date changed from 1 Dec 2016 to 31 Mar 2017.
- 10 Oct 2016 Results (n=37) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.